MacroGenics Inc Stock Plunges Over 50% After Trial Results Reveal High Adverse Events Rate
On May 10, 2024, in an alarming development, MacroGenics Inc, based in Rockville, Maryland, revealed concerning interim data from the TAMARACK Phase 2 study. The study focused on vobramitamab duocarmazine (vobra duo), a treatment targeting B7-H3, which is found in various solid tumors. Specifically, the study targeted previously treated patients with metastatic castration-resistant prostate cancer (mCRPC). Following the release of the data, MacroGenics shares plummeted by over 50% as the company disclosed five deaths during …